Gregory Orloff, MD
Hematology & Oncology · Fairfax, VANPI 1750358776
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 25.8% of the total. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 54 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$332
- Bristol Myers Squibb$132
- Daiichi Sankyo Inc.$127
- Incyte Corporation$66
- Novartis$64
- Amgen$60
- plus $507 from 17 others
Across 46 payments — averaging $5820.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$244K
- E.r. Squibb & Sons, L.L.C.$23K
What the payments were for
- Food & beverage$1,19292%
- Education$978%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $332 |
| Bristol Myers Squibb | 5 | $132 |
| Daiichi Sankyo Inc. | 6 | $127 |
| Incyte Corporation | 3 | $66 |
| Novartis | 3 | $64 |
| Amgen | 3 | $60 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Bioprotect Medical, Inc. | 1 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Pfizer | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| Iovance Biotherapeutics, Inc. | 1 | $36 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $35 |
| Merck | 2 | $34 |
| Tersera Therapeutics LLC | 1 | $33 |
| Genentech USA, Inc. | 2 | $29 |
| Sanofi | 1 | $29 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$1,289 in reported general payments places this provider in the 50th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 68 | $844,291 |
| RevlimidLenalidomide | 30 | $510,213 |
| PomalystPomalidomide | 25 | $422,893 |
| JakafiRuxolitinib Phosphate | 13 | $224,838 |
| BrukinsaZanubrutinib | 17 | $216,912 |
| ImbruvicaIbrutinib | 13 | $212,242 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $187,410 |
| TafinlarDabrafenib Mesylate | 12 | $172,592 |
| EliquisApixaban | 55 | $41,991 |
| Imatinib Mesylate | 12 | $35,277 |
| Hydroxyurea | 22 | $1,829 |
| Acyclovir | 90 | $1,543 |
| Dexamethasone | 57 | $1,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $132 | $510,21330 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $39 | $422,89325 claims |
| NovartisMekinist, Tafinlar | $64 | $360,00224 claims |
| Incyte CorporationJakafi | $66 | $224,83813 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $212,24213 claims |
| PfizerEliquis | $38 | $41,99155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Fairfax
- William ErshlerFairfax$139K
- Sekwon JangFairfax$56K
- Raymond WadlowFairfax$30K
- Daniel ChongFairfax$15K
- Mohamad SalkeniFairfax$12K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.